分化型甲状腺癌靶向药物治疗研究进展  

Advances in Targeted Drug Therapy for Differentiated Thyroid Carcinoma

作　　者：韦雨策 柴玥 张娣 董梅 WEI Yuce;CHAI Yue;ZHANG Di;DONG Mei(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科,北京100021

出　　处：《医学综述》2022年第19期3827-3834,共8页Medical Recapitulate

摘　　要：甲状腺癌总体预后良好,多数分化型甲状腺癌(DTC)患者治疗后可获长期生存,但亦有部分进展性放射性碘难治性DTC患者预后极差。甲状腺癌靶向药物治疗广义上包括抗血管生成酪氨酸激酶抑制剂、针对特定基因突变的靶向药物、针对融合基因的靶向药物、免疫治疗、肽受体放射性核素治疗等。多种靶向药物现已获批使用,亦有多种药物处于Ⅱ、Ⅲ期临床试验阶段,有望投入临床应用。靶向治疗已成为晚期甲状腺癌患者治疗中不可或缺的组成部分,具有广阔的临床应用前景。The overall prognosis of thyroid cancer is good,and most patients with differentiated thyroid carcinoma(DTC)can achieve long-term survival while some with progressive,radioactive iodine-refractory DTC turned out to have poor prognosis.Targeted therapy for thyroid cancer,in its widest sense,includes antiangiogenic tyrosine kinase inhibitor,targeted therapy for specific genetic mutations,targeted therapy for fusion genes,immunotherapy,peptide receptor radionuclide therapy,etc.Some medications have already gained official approval,and a variety of new ones are currently in phaseⅡ/Ⅲtrials,expected to be put into clinical application.Targeted therapy has already become an indispensable component of treatment for advanced thyroid cancer and has a broad clinical application prospect.

关 键 词：甲状腺肿瘤 分子靶向治疗 酪氨酸激酶抑制剂 免疫治疗 

分 类 号：R736.1[医药卫生—肿瘤]